Brief: Oncopeptides Intends To Submit Type II Variation Application

Oncopeptides AB

11/05/2026 07:25

May 11 (Reuters) - Oncopeptides AB ONCO.ST:

INTENDS TO SUBMIT TYPE II VARIATION TO EXPAND PEPAXTI LABEL TO INCLUDE THIRD LINE TREATMENT

TO SUBMIT APPLICATION DURING COMING MONTHS

EXPECTS FIRST REGULATORY FEEDBACK BEFORE END OF 2026 WITH SUBSEQUENT FINAL DECISION BY EUROPEAN COMMISSION IN H1 2027

Source text: ID:nMFN65h6VC

Further company coverage: ONCO.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))